Cole P T
Cancer. 1977 Apr;39(4 Suppl):1906-8. doi: 10.1002/1097-0142(197704)39:4+<1906::aid-cncr2820390827>3.0.co;2-b.
The continued high prevalence of oral contraceptive (OC) use by young women warrants the careful study of these agents. At present, it appears that the risk of benign breast disease is reduced by use of OCs. This effect seems to be greater for fibrocystic disease than for fibroadenoma. Available information suggests that, as yet, OC use has not had any effect on breast cancer risk. The recent slight rise in breast cancer rates in younger women has not been shown to be due to OC use. The relationship between OCs and breast cancer may not become clear for another 5 to 10 years because of the long latent period of this disease. Meanwhile, for reasons presented, it would seem wise not to prescribe OCs for women with a history of benign breast disease and to withdraw them from women who develop these conditions.
年轻女性持续高比例使用口服避孕药（OC），这使得对这些药物进行仔细研究很有必要。目前，使用OC似乎可降低患良性乳腺疾病的风险。这种作用对纤维囊性疾病的影响似乎比对纤维腺瘤的影响更大。现有信息表明，目前OC的使用对乳腺癌风险尚无任何影响。尚未证实年轻女性近期乳腺癌发病率的轻微上升是由使用OC所致。由于乳腺癌的潜伏期较长，OC与乳腺癌之间的关系可能在未来5至10年内都不会明确。同时，基于上述原因，对于有良性乳腺疾病史的女性，似乎明智的做法是不开具OC处方，并让已出现这些病症的女性停用OC。
